BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 12557698)

  • 1. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K; Babaian RJ
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostate-specific antigen].
    Eide IA; Angelsen A
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
    Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
    Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K; Higashihara E
    Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
    Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
    Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
    Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
    Kawai M; Okajima K; Kobayashi K; Moriyama M
    Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of PSA-density: analysis in PSA gray zone cases].
    Ishizuka O; Iwata K; Igawa Y; Nishizawa O
    Hinyokika Kiyo; 2001 Sep; 47(9):611-3. PubMed ID: 11692595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostate cancer].
    Uchida K; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.